In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376.

MLA

Maggi, C. A., et al. “In Vivo Evidence for Tachykininergic Transmission Using a New NK-2 Receptor-Selective Antagonist, MEN 10,376.” The Journal of Pharmacology and Experimental Therapeutics, vol. 257, no. 3, June 1991, pp. 1172–78. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=1710662&authtype=sso&custid=ns315887.

APA

Maggi, C. A., Giuliani, S., Ballati, L., Lecci, A., Manzini, S., Patacchini, R., Renzetti, A. R., Rovero, P., Quartara, L., & Giachetti, A. (1991). In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. The Journal of Pharmacology and Experimental Therapeutics, 257(3), 1172–1178.

Chicago

Maggi, C A, S Giuliani, L Ballati, A Lecci, S Manzini, R Patacchini, A R Renzetti, P Rovero, L Quartara, and A Giachetti. 1991. “In Vivo Evidence for Tachykininergic Transmission Using a New NK-2 Receptor-Selective Antagonist, MEN 10,376.” The Journal of Pharmacology and Experimental Therapeutics 257 (3): 1172–78. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=1710662&authtype=sso&custid=ns315887.